Apellis Pharmaceuticals (APLS) PT Raised to $60 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $60.00 (from $39.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Siltronic AG (WAF:GR) (SSLLF) PT Raised to EUR123 at UBS
- Citi Upgrades Technogym SpA (TGYM:IM) (TCCHF) to Buy
- Nomad Foods Ltd (NOMD) PT Raised to $15 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
